FAIR VALUE - Narrative (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2020 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration		$ 14,900,000		$ 14,900,000		$ 26,300,000
Long-term contingent consideration		27,600,000		27,600,000		22,200,000
Change in fair value of contingent consideration		241,000	$ 1,300,000	9,408,000	$ 2,945,000
Level 2
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Debt conversion option value		64,600,000		64,600,000		92,500,000
Convertible notes, par value		$ 40,000,000		$ 40,000,000		70,000,000
Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.35		0.35
Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.090		0.090
Discounted Cash Flow | Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.046		0.046
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, royalty percentage	20.00%
INDOCIN
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration		$ 42,500,000		$ 42,500,000		48,500,000
Short-term contingent consideration		14,900,000		14,900,000		26,300,000
Long-term contingent consideration		$ 27,600,000		$ 27,600,000		$ 22,200,000
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000